Literature DB >> 19545760

Urachal adenocarcinoma following kidney transplantation: the first case report.

H-C Tai1, Y-S Chen, S-M Wang, S-C Chueh, M-K Lai, H-J Yu.   

Abstract

A 53-year-old man who underwent successful kidney transplantation for stage 5 chronic kidney disease presented to our clinic with intermittent painless gross hematuria. Urachal adenocarcinoma, stage III A by Sheldon system, was diagnosed after serial histopathologic and radiological studies. The patient was treated with extended partial cystectomy, en bloc resection of urachus and umbilicus, pelvic lymphadenectomy, and ileocystoplasty. There were no complications seen in this patient. Neither urachal adenocarcinoma recurrence, metastasis, nor de novo uroileal cancer developed during 48-month follow-up. His reconstructed bladder functioned efficiently, without compromising the transplanted kidney function. Our case demonstrated that conservative surgery and augmentation ileocystoplasty could be offered to kidney transplant recipients with localized urachal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545760     DOI: 10.1016/j.transproceed.2009.03.072

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  A Case of Urachal Carcinoma of the Abdominal Wall in a Kidney Transplant Recipient.

Authors:  Takuya Yamazaki; Yasushi Nagaba; Yoshitaka Shimada; Yoshinori Taoka; Satoru Minamida; Dai Koguchi; Masahiro Hagiwara; Sho Watanuki; Hide Nagaba; Kazunari Yoshida; Yasuo Takeuchi
Journal:  Case Rep Med       Date:  2017-05-04

2.  Extended partial cystectomy with augmentation cystoplasty in urachal adenocarcinoma: An oncologically favorable but underutilized alternative to radical cystectomy.

Authors:  Rohan Satish Valsangkar; Syed J Rizvi; Niraj K Goyal
Journal:  Urol Ann       Date:  2016 Jul-Sep

Review 3.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.